Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stem Cell Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Stem Cell Pharmaceuticals has several composition of matter and use patents on members of a family of growth factors that cause resident adult stem cells to proliferate, migrate to a site of injury, and differentiate into the type of cell that's needed. It aims to develop an injectable drug that will enhance a patient's own stem cell-based repair mechanisms, providing a therapy that is much safer and easier to administer than stem cell transplantation, company founders believe.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts